Five things for pharma marketers to know: Monday, October 2, 2017
1. The FDA sent letters to 75 immediate-release opioid manufacturers, in which the agency told the drugmakers that they must fund voluntary training of healthcare providers who prescribe their drugs. (Reuters)
2. In its first Phase-III trial, Zogenix' experimental treatment for a rare form of epilepsy, ZX008, reduced the frequency of seizures in children and young adults.
3. The FDA approved Novo Nordisk's fast-acting mealtime insulin, Fiasp. The drug is a new formulation of Novolog.
4. Medicare lost $1.5 billion on defective pacemakers and other devices, according to a report released by the inspector general's office for the Department of Health and Human Services. The report discovered that nearly 73,000 Medicare patients had one of the seven defective devices replaced. (NYT)
5. ICYMI: Lobbying group PhRMA said it supports a seven-day limit on first-time opioid prescriptions for acute pain. (BioPharmaDIVE)